Annual EBIT
-$143.31 M
-$30.93 M-27.52%
31 December 2023
Summary:
Monte Rosa Therapeutics annual earnings before interest & taxes is currently -$143.31 million, with the most recent change of -$30.93 million (-27.52%) on 31 December 2023. During the last 3 years, it has fallen by -$115.30 million (-411.64%). GLUE annual EBIT is now -1751.80% below its all-time high of -$7.67 million.GLUE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$26.53 M
+$6.12 M+18.73%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly earnings before interest & taxes is currently -$26.53 million, with the most recent change of +$6.12 million (+18.73%) on 30 September 2024. Over the past year, it has increased by +$10.44 million (+28.24%). GLUE quarterly EBIT is now -517.05% below its all-time high of -$4.30 million, reached on 31 March 2020.GLUE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$128.98 M
+$10.44 M+7.49%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM earnings before interest & taxes is currently -$128.98 million, with the most recent change of +$10.44 million (+7.49%) on 30 September 2024. Over the past year, it has increased by +$11.96 million (+8.48%). GLUE TTM EBIT is now -2900.21% below its all-time high of -$4.30 million, reached on 31 March 2020.GLUE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.5% | +28.2% | +8.5% |
| 3 y3 years | -411.6% | -33.5% | -110.0% |
| 5 y5 years | - | - | - |
GLUE EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -411.6% | at low | -33.5% | +28.7% | -110.0% | +10.4% |
| 5 y | 5 years | -1751.8% | at low | -517.0% | +28.7% | -2900.2% | +10.4% |
| alltime | all time | -1751.8% | at low | -517.0% | +28.7% | -2900.2% | +10.4% |
Monte Rosa Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$26.53 M(-18.7%) | -$128.98 M(-7.5%) |
| June 2024 | - | -$32.64 M(-6.6%) | -$139.42 M(-3.2%) |
| Mar 2024 | - | -$34.95 M(+0.2%) | -$144.00 M(+0.5%) |
| Dec 2023 | -$143.31 M(+27.5%) | -$34.86 M(-5.7%) | -$143.31 M(+1.7%) |
| Sept 2023 | - | -$36.97 M(-0.7%) | -$140.94 M(+6.5%) |
| June 2023 | - | -$37.22 M(+8.6%) | -$132.33 M(+8.2%) |
| Mar 2023 | - | -$34.26 M(+5.4%) | -$122.34 M(+8.9%) |
| Dec 2022 | -$112.38 M | -$32.49 M(+14.6%) | -$112.38 M(+8.8%) |
| Sept 2022 | - | -$28.36 M(+4.2%) | -$103.28 M(+9.0%) |
| June 2022 | - | -$27.23 M(+12.1%) | -$94.79 M(+10.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$24.30 M(+3.9%) | -$85.68 M(+17.6%) |
| Dec 2021 | -$72.88 M(+160.2%) | -$23.39 M(+17.7%) | -$72.88 M(+18.6%) |
| Sept 2021 | - | -$19.87 M(+9.6%) | -$61.43 M(+28.1%) |
| June 2021 | - | -$18.12 M(+57.5%) | -$47.95 M(+36.1%) |
| Mar 2021 | - | -$11.50 M(-3.6%) | -$35.22 M(+25.7%) |
| Dec 2020 | -$28.01 M(+261.9%) | -$11.94 M(+86.9%) | -$28.02 M(+74.2%) |
| Sept 2020 | - | -$6.39 M(+18.3%) | -$16.08 M(+65.9%) |
| June 2020 | - | -$5.40 M(+25.5%) | -$9.70 M(+125.5%) |
| Mar 2020 | - | -$4.30 M | -$4.30 M |
| Dec 2019 | -$7.74 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual EBIT year-on-year change?
- What is Monte Rosa Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly EBIT year-on-year change?
- What is Monte Rosa Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM EBIT year-on-year change?
What is Monte Rosa Therapeutics annual earnings before interest & taxes?
The current annual EBIT of GLUE is -$143.31 M
What is the all time high annual EBIT for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual earnings before interest & taxes is -$7.67 M
What is Monte Rosa Therapeutics annual EBIT year-on-year change?
Over the past year, GLUE annual earnings before interest & taxes has changed by -$30.93 M (-27.52%)
What is Monte Rosa Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of GLUE is -$26.53 M
What is the all time high quarterly EBIT for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly earnings before interest & taxes is -$4.30 M
What is Monte Rosa Therapeutics quarterly EBIT year-on-year change?
Over the past year, GLUE quarterly earnings before interest & taxes has changed by +$10.44 M (+28.24%)
What is Monte Rosa Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of GLUE is -$128.98 M
What is the all time high TTM EBIT for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM earnings before interest & taxes is -$4.30 M
What is Monte Rosa Therapeutics TTM EBIT year-on-year change?
Over the past year, GLUE TTM earnings before interest & taxes has changed by +$11.96 M (+8.48%)